Clinical trial
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active…
NCT00408629 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00408629 |
|---|---|
| Title | Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Biological |
| Interventions | adalimumab, placebo |
| Enrollment | 518 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Dec 7, 2006 |
| Last update posted | May 3, 2011 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, New Zealand and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: